Mahmut Akpek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mahmut Akpek has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
Mehmet G. Kaya
Department of Cardiology, Erciyes University School of Medicine, Kayseri, Turkey
7 shared publications- Mikail Yarlioglues
Department of Cardiology, Ankara Education and Research Hospital, Ankara, Turkey
7 shared publications - Deniz Elcik
Department of Cardiology, Erciyes University Faculty of Medicine, Kayseri, Turkey
6 shared publications Ali Ergin
Department of Cardiology, Erciyes University School of Medicine, Kayseri, Turkey
5 shared publicationsBahadir Sarli
Department of Cardiology, Kayseri Education and Research Hospital, Kayseri, Turkey
5 shared publications- Idris Ardic
Department of Cardiology, Medicine Faculty of Erciyes University, Kayseri, Turkey
5 shared publications
Latest Publications
- Open Access
- 9 November 2022
- Published by Academician Publishing
Geriatrik Ortopedi ve Travmatoloji Cilt I
Evet tıp, yaşlılığı geciktirecektir hem de mekanizmanın tüm sistemlerinde bu hastalığı! geciktirecektir. Hatta ölüme dahi çare bulacaktır. Ancak bu işlemlerin tamamı geçici olacak ve hiçbir tedavi ve çözüm, kalıcı olmayacaktır. YAŞLILIK, ZAMANI GENETİK KODLARDA BELİRLENMİŞ, OKSİDATİF BİR KANUN-U İLAHİDİR. Bu bakımdan tıbbın bu asırda ilgilenmek zorunda kalacağı bu bölüm, en zor ve en fazla bilinmeyeni içinde barındıran bir bölüm olacaktır. Bu bakımdan bu nüfusunda ayrı bir kliniği, ayrı bir uzmanlık dalının olması gerekmektedir. Çünkü yaşlılığın, farklı bir mekanizmaya, farklı bir fizyolojiye sahip olduğu artık bilinmektedir.
- 9 November 2022
- Published by Academician Publishing
Open AccessGeriatrik Ortopedi ve Travmatoloji Cilt I
Evet tıp, yaşlılığı geciktirecektir hem de mekanizmanın tüm sistemlerinde bu hastalığı! geciktirecektir. Hatta ölüme dahi çare bulacaktır. Ancak bu işlemlerin tamamı geçici olacak ve hiçbir tedavi ve çözüm, kalıcı olmayacaktır. YAŞLILIK, ZAMANI GENETİK KODLARDA BELİRLENMİŞ, OKSİDATİF BİR KANUN-U İLAHİDİR. Bu bakımdan tıbbın bu asırda ilgilenmek zorunda kalacağı bu bölüm, en zor ve en fazla bilinmeyeni içinde barındıran bir bölüm olacaktır. Bu bakımdan bu nüfusunda ayrı bir kliniği, ayrı bir uzmanlık dalının olması gerekmektedir. Çünkü yaşlılığın, farklı bir mekanizmaya, farklı bir fizyolojiye sahip olduğu artık bilinmektedir.
- Top Cited Papers
- 10 December 2021
- Published by SAGE Publications in Angiology
- Vol. 73 (7) , 682-687
Does COVID-19 Cause Hypertension?
The coronavirus disease 2019 (COVID-19) outbreak remains a major public health challenge worldwide. The present study investigated the effect of COVID-19 on blood pressure (BP) during short term follow-up. A total of 211 consecutive COVID-19 patients who were admitted to Parkhayat Kutahya hospital were retrospectively screened. Information was obtained from the electronic medical records and National health data registry. The study outcome was new onset of hypertension according to the Eight Joint National Committee and European Society of Cardiology Guidelines. Finally, 153 confirmed COVID-19 patients (mean age 46.5 ± 12.7 years) were enrolled. Both systolic (120.9 ± 7.2 vs 126.5 ± 15.0 mmHg, P <.001) and diastolic BP (78.5 ± 4.4 vs 81.8 ± 7.4 mmHg, P <.001) were significantly higher in the post COVID-19 period than on admission. New onset hypertension was observed in 18 patients at the end of 31.6 ± 5.0 days on average (P <.001). These findings suggest that COVID-19 increases systolic and diastolic BP and may cause new onset hypertension.
- 10 December 2021
- Published by SAGE Publications in Angiology
- Vol. 73 (7) , 682-687
Top Cited PapersDoes COVID-19 Cause Hypertension?
The coronavirus disease 2019 (COVID-19) outbreak remains a major public health challenge worldwide. The present study investigated the effect of COVID-19 on blood pressure (BP) during short term follow-up. A total of 211 consecutive COVID-19 patients who were admitted to Parkhayat Kutahya hospital were retrospectively screened. Information was obtained from the electronic medical records and National health data registry. The study outcome was new onset of hypertension according to the Eight Joint National Committee and European Society of Cardiology Guidelines. Finally, 153 confirmed COVID-19 patients (mean age 46.5 ± 12.7 years) were enrolled. Both systolic (120.9 ± 7.2 vs 126.5 ± 15.0 mmHg, P <.001) and diastolic BP (78.5 ± 4.4 vs 81.8 ± 7.4 mmHg, P <.001) were significantly higher in the post COVID-19 period than on admission. New onset hypertension was observed in 18 patients at the end of 31.6 ± 5.0 days on average (P <.001). These findings suggest that COVID-19 increases systolic and diastolic BP and may cause new onset hypertension.
- Open Access
- 22 August 2016
- Published by S. Karger AG in Medical Principles and Practice
- Vol. 25 (6) , 577-579
Simultaneous Use of Intravenous Lipid Emulsion and Plasma Exchange Therapies in Multiple Drug Toxicity
Objective: The aim of this study was to highlight the use of combined intravenous lipid emulsion (ILE) and plasma exchange (PE) therapies in multidrug toxicity. Clinical Presentation and Intervention: A 45-year-old woman who attempted suicide by ingesting large quantities of amisulpride (28 g), diazepam (250 mg), valsartan (2,240 mg), aripiprazole (45 mg) and paliperidone (21 mg) was taken to the hospital of Adnan Menderes University School of Medicine. Upon arrival, she exhibited signs of cardiotoxicity and severe depression of the central nervous and respiratory systems. She was treated successfully with ILE for 4 h and PE therapy for 36 h, consecutively. She was discharged on the fourth day of hospitalization having fully recovered. Conclusion: The patient was successfully treated with the combination of ILE and PE.
- 22 August 2016
- Published by S. Karger AG in Medical Principles and Practice
- Vol. 25 (6) , 577-579
Open AccessSimultaneous Use of Intravenous Lipid Emulsion and Plasma Exchange Therapies in Multiple Drug Toxicity
Objective: The aim of this study was to highlight the use of combined intravenous lipid emulsion (ILE) and plasma exchange (PE) therapies in multidrug toxicity. Clinical Presentation and Intervention: A 45-year-old woman who attempted suicide by ingesting large quantities of amisulpride (28 g), diazepam (250 mg), valsartan (2,240 mg), aripiprazole (45 mg) and paliperidone (21 mg) was taken to the hospital of Adnan Menderes University School of Medicine. Upon arrival, she exhibited signs of cardiotoxicity and severe depression of the central nervous and respiratory systems. She was treated successfully with ILE for 4 h and PE therapy for 36 h, consecutively. She was discharged on the fourth day of hospitalization having fully recovered. Conclusion: The patient was successfully treated with the combination of ILE and PE.
- 2 February 2015
- Published by Wiley in Echocardiography
- Vol. 32 (10) , 1477-1482
Association of Left Atrial Spontaneous Echo Contrast to Uric Acid in Patients with Mitral Stenosis
Spontaneous echo contrast (SEC) is the presence of smoke-like echoes with a characteristic swirling motion of the blood in echocardiography. Previous clinical studies have shown that SEC is a risk factor for left atrial thrombus formation and a predictor of potential systemic embolism originating from the heart. There is an association between uric acid and prothrombotic state. Therefore, we aimed to investigate the role of uric acid in SEC in patients with mitral stenosis (MS).A total of 85 consecutive patients with MS were enrolled in the study. Patients were divided into two groups according to whether SEC was present in the left atrium.There were 41 patients (mean age 46.4 ± 11.4 and 68% female) in the SEC(-) group and 44 patients (mean age 45.7 ± 7.2 and 64% female) in the SEC(+) group. High sensitive C-reactive protein (hs-CRP) levels were significantly higher in the SEC(+) group than in the SEC(-) group (9.5 ± 4.2 vs. 4.7 ± 2.2 mg/L, P < 0.001). Uric acid was also significantly higher in the SEC (+) group (6.3 ± 1.4 vs. 4.5 ± 1.3 mg/dL, P < 0.001). In receiver operating characteristics curve analysis, uric acid >5.2 mg/dL had a 73% sensitivity and 76% specificity in predicting SEC in patients with MS. At multivariate analysis, uric acid (OR 3.919, 95% CI 1.911-8.035; P < 0.002) was an independent risk factor for SEC in patients with MS.Uric acid is independently associated with SEC in patients with MS. Our findings suggest that this inexpensive, universally available marker may be a useful biomarker for the stratification of risk in patients with MS.
- 2 February 2015
- Published by Wiley in Echocardiography
- Vol. 32 (10) , 1477-1482
Association of Left Atrial Spontaneous Echo Contrast to Uric Acid in Patients with Mitral Stenosis
Spontaneous echo contrast (SEC) is the presence of smoke-like echoes with a characteristic swirling motion of the blood in echocardiography. Previous clinical studies have shown that SEC is a risk factor for left atrial thrombus formation and a predictor of potential systemic embolism originating from the heart. There is an association between uric acid and prothrombotic state. Therefore, we aimed to investigate the role of uric acid in SEC in patients with mitral stenosis (MS).A total of 85 consecutive patients with MS were enrolled in the study. Patients were divided into two groups according to whether SEC was present in the left atrium.There were 41 patients (mean age 46.4 ± 11.4 and 68% female) in the SEC(-) group and 44 patients (mean age 45.7 ± 7.2 and 64% female) in the SEC(+) group. High sensitive C-reactive protein (hs-CRP) levels were significantly higher in the SEC(+) group than in the SEC(-) group (9.5 ± 4.2 vs. 4.7 ± 2.2 mg/L, P < 0.001). Uric acid was also significantly higher in the SEC (+) group (6.3 ± 1.4 vs. 4.5 ± 1.3 mg/dL, P < 0.001). In receiver operating characteristics curve analysis, uric acid >5.2 mg/dL had a 73% sensitivity and 76% specificity in predicting SEC in patients with MS. At multivariate analysis, uric acid (OR 3.919, 95% CI 1.911-8.035; P < 0.002) was an independent risk factor for SEC in patients with MS.Uric acid is independently associated with SEC in patients with MS. Our findings suggest that this inexpensive, universally available marker may be a useful biomarker for the stratification of risk in patients with MS.
- 20 November 2014
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 17 (1) , 81-89
Protective Effects of Spironolactone Against Anthracycline-Induced Cardiomyopathy
Aims The protective effect of beta‐blockers, ACE inhibitors, and ARBs on anthracycline cardiotoxicity has already been demonstrated, but the effect of aldosterone antagonism, which inhibits the last step of the renin–angiotensin–aldosterone system (RAAS), was questioned. This study sought to investigate whether spironolactone protects the heart against anthracycline‐induced cardiotoxicity. Methods and results Eighty‐three female patients who were diagnosed with breast cancer were included in the study. The study population was randomized into spironolactone and control groups. A dose of 25 mg/day spironolactone was administered to the patients in the spironolactone group. There were 43 patients (mean age 50 ± 11 years) in the spironolactone group and 40 patients (mean age 51 ± 10 years) in the control group. LVEF decreased from 67.0 ± 6.1 to 65.7 ± 7.4 (P = 0.094) in the spironolactone group, and from 67.7 ± 6.3 to 53.6 ± 6.8 in the control group (P < 0.001). When the general linear model was applied, the interaction of LVEF decrease between groups was significantly lower in the spironolactone group than in the control group (P < 0.001). The diastolic functional grade of subjects in the spironolactone group was protected (P = 0.096), whereas it deteriorated in the control group (P < 0.001). Conclusion We showed that spironolactone administration used simultaneously with anthracycline group chemotherapeutics protects both myocardial systolic and diastolic functions. Spironolactone can be used to protect against anthracycline‐induced cardiotoxicity. Trial registration: NCT02053974.
- 20 November 2014
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 17 (1) , 81-89
Protective Effects of Spironolactone Against Anthracycline-Induced Cardiomyopathy
Aims The protective effect of beta‐blockers, ACE inhibitors, and ARBs on anthracycline cardiotoxicity has already been demonstrated, but the effect of aldosterone antagonism, which inhibits the last step of the renin–angiotensin–aldosterone system (RAAS), was questioned. This study sought to investigate whether spironolactone protects the heart against anthracycline‐induced cardiotoxicity. Methods and results Eighty‐three female patients who were diagnosed with breast cancer were included in the study. The study population was randomized into spironolactone and control groups. A dose of 25 mg/day spironolactone was administered to the patients in the spironolactone group. There were 43 patients (mean age 50 ± 11 years) in the spironolactone group and 40 patients (mean age 51 ± 10 years) in the control group. LVEF decreased from 67.0 ± 6.1 to 65.7 ± 7.4 (P = 0.094) in the spironolactone group, and from 67.7 ± 6.3 to 53.6 ± 6.8 in the control group (P < 0.001). When the general linear model was applied, the interaction of LVEF decrease between groups was significantly lower in the spironolactone group than in the control group (P < 0.001). The diastolic functional grade of subjects in the spironolactone group was protected (P = 0.096), whereas it deteriorated in the control group (P < 0.001). Conclusion We showed that spironolactone administration used simultaneously with anthracycline group chemotherapeutics protects both myocardial systolic and diastolic functions. Spironolactone can be used to protect against anthracycline‐induced cardiotoxicity. Trial registration: NCT02053974.
- 4 August 2014
- Published by SAGE Publications in Angiology
- Vol. 66 (6) , 560-567
Acute Effects of Intracoronary Tirofiban on No-Reflow Phenomena in Patients With ST-Segment Elevated Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
We evaluated the acute effect of intracoronary administration of tirofiban on no-reflow phenomenon in patients with ST-segment elevated myocardial infarction undergoing primary percutaneous coronary intervention. Consecutive patients (n = 162) were randomized into 2 groups based on whether intracoronary tirofiban was administered. After the administration of intracoronary tirofiban, thrombolysis in myocardial infarction (TIMI) flow grade significantly increased (P < .001) and successful reperfusion was achieved in 26 (32%) patients. In the placebo group, however, after the administration of intracoronary placebo the TIMI flow grade did not change (P = .070), and successful reperfusion was achieved only in 8 (10%) patients. In-hospital major adverse cardiac events (MACE) were significantly lower in the tirofiban group (36% vs 19%, P = .013). Intracoronary administration of tirofiban significantly improves TIMI flow grade and is associated with a lower in-hospital rate of MACE.
- 4 August 2014
- Published by SAGE Publications in Angiology
- Vol. 66 (6) , 560-567
Acute Effects of Intracoronary Tirofiban on No-Reflow Phenomena in Patients With ST-Segment Elevated Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
We evaluated the acute effect of intracoronary administration of tirofiban on no-reflow phenomenon in patients with ST-segment elevated myocardial infarction undergoing primary percutaneous coronary intervention. Consecutive patients (n = 162) were randomized into 2 groups based on whether intracoronary tirofiban was administered. After the administration of intracoronary tirofiban, thrombolysis in myocardial infarction (TIMI) flow grade significantly increased (P < .001) and successful reperfusion was achieved in 26 (32%) patients. In the placebo group, however, after the administration of intracoronary placebo the TIMI flow grade did not change (P = .070), and successful reperfusion was achieved only in 8 (10%) patients. In-hospital major adverse cardiac events (MACE) were significantly lower in the tirofiban group (36% vs 19%, P = .013). Intracoronary administration of tirofiban significantly improves TIMI flow grade and is associated with a lower in-hospital rate of MACE.
- 1 January 2014
- Vol. 42 (1)
Case images: a giant calcified left ventricular aneurysm.
- 1 June 2013
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 24 (4) , 285-289
Mean platelet volume is associated with poor postinterventional myocardial blush grade in patients with ST-segment elevation myocardial infarction
Objective In a significant proportion of patients with ST-elevation myocardial infarction (STEMI), microvascular and myocardial reperfusion cannot be regained despite successfully restored thrombolysis in myocardial infarction (TIMI) grade 3 epicardial blood flow. Myocardial blush grade (MBG) is a reliable marker for microvascular patency and predicts short-term and long-term mortality after primary percutaneous coronary intervention (PCI) in patients with acute STEMI, independent of other variables. Mean platelet volume (MPV), a unique measure of platelet size, is an indicator of platelet reactivity. In this study, we aimed to investigate the relation of admission MPV with postinterventional MBG in patients with STEMI and TIMI grade 3 flow at infarct artery after primary PCI. Materials and methods Three hundred and ten patients were selected as a study group among patients with STEMI and TIMI grade 3 epicardial blood flow after primary PCI. Blood samples for analysis were obtained during the initial evaluation of patients at the emergency department. MBGs of patients were classified at the end of angioplasty. Patients with MBG 0 and 1 were defined as having poor myocardial blush and patients with MBG 2 and 3 were defined as having normal myocardial blush. Results Patients with poor myocardial blush had higher admission MPV (10.5±1.3 to 9.1±1 fl, PP3/μl, P=0.012), and lower left ventricular ejection fraction (42±7 to 51±8%, PPP=0.013) and acute–subacute stent thrombosis at 3 months (12–8%, P=0.028) were significantly higher in patients with poor postinterventional myocardial blush compared with those with normal myocardial blush. Conclusion The MPV measured at admission is significantly associated with poor postinterventional MBG in patients with STEMI and TIMI grade 3 flow at infarct artery after primary PCI.
- 1 June 2013
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 24 (4) , 285-289
Mean platelet volume is associated with poor postinterventional myocardial blush grade in patients with ST-segment elevation myocardial infarction
Objective In a significant proportion of patients with ST-elevation myocardial infarction (STEMI), microvascular and myocardial reperfusion cannot be regained despite successfully restored thrombolysis in myocardial infarction (TIMI) grade 3 epicardial blood flow. Myocardial blush grade (MBG) is a reliable marker for microvascular patency and predicts short-term and long-term mortality after primary percutaneous coronary intervention (PCI) in patients with acute STEMI, independent of other variables. Mean platelet volume (MPV), a unique measure of platelet size, is an indicator of platelet reactivity. In this study, we aimed to investigate the relation of admission MPV with postinterventional MBG in patients with STEMI and TIMI grade 3 flow at infarct artery after primary PCI. Materials and methods Three hundred and ten patients were selected as a study group among patients with STEMI and TIMI grade 3 epicardial blood flow after primary PCI. Blood samples for analysis were obtained during the initial evaluation of patients at the emergency department. MBGs of patients were classified at the end of angioplasty. Patients with MBG 0 and 1 were defined as having poor myocardial blush and patients with MBG 2 and 3 were defined as having normal myocardial blush. Results Patients with poor myocardial blush had higher admission MPV (10.5±1.3 to 9.1±1 fl, PP3/μl, P=0.012), and lower left ventricular ejection fraction (42±7 to 51±8%, PPP=0.013) and acute–subacute stent thrombosis at 3 months (12–8%, P=0.028) were significantly higher in patients with poor postinterventional myocardial blush compared with those with normal myocardial blush. Conclusion The MPV measured at admission is significantly associated with poor postinterventional MBG in patients with STEMI and TIMI grade 3 flow at infarct artery after primary PCI.
- 22 April 2013
- Published by Elsevier in The American Journal of Cardiology
- Vol. 112 (2) , 187-193
Usefulness of Monocyte Chemoattractant Protein-1 to Predict No-Reflow and Three-Year Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
- 22 April 2013
- Published by Elsevier in The American Journal of Cardiology
- Vol. 112 (2) , 187-193
Usefulness of Monocyte Chemoattractant Protein-1 to Predict No-Reflow and Three-Year Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention